Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Experts say the ACR/AAHKS 2022 guidelines for patients undergoing total hip replacement or total knee replacement have several limitations that limit the effectiveness of their recommendations.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Less Mental Decline With Darolutamide vs Enzalutamide in PC
2.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
3.
MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy
4.
Breast cancer-related fatigue: The benefits of adapted physical activity
5.
Except for Black Patients, the Rates of Gallbladder Cancer Are Stable or Declining.
1.
Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology
2.
Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide
3.
Tumor Microenvironment Readiness as a Predictor of Cancer Progression
4.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
5.
What Is A High MCV Level? Causes, Symptoms, And Treatment Options
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge